<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.4//EN" "ep-patent-document-v1-4.dtd">
<ep-patent-document id="EP09151443B8W1" file="EP09151443W1B8.xml" lang="en" country="EP" doc-number="2070920" kind="B8" correction-code="W1" date-publ="20110427" status="c" dtd-version="ep-patent-document-v1-4">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIE......FI..........................................................</B001EP><B005EP>J</B005EP><B007EP>DIM360 Ver 2.15 (14 Jul 2008) -  2999001/0</B007EP></eptags></B000><B100><B110>2070920</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20110427</date></B140><B150><B151>W1</B151><B153>72</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>09151443.0</B210><B220><date>19970724</date></B220><B240><B241><date>20091210</date></B241><B242><date>20100113</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>690258</B310><B320><date>19960724</date></B320><B330><ctry>US</ctry></B330><B310>701494</B310><B320><date>19960822</date></B320><B330><ctry>US</ctry></B330><B310>48278 P</B310><B320><date>19970530</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20110427</date><bnum>201117</bnum></B405><B430><date>20090617</date><bnum>200925</bnum></B430><B450><date>20110302</date><bnum>201109</bnum></B450><B452EP><date>20101116</date></B452EP><B480><date>20110427</date><bnum>201117</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>C07D 401/04        20060101AFI20090504BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>A61K  31/445       20060101ALI20090504BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen</B542><B541>en</B541><B542>Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels</B542><B541>fr</B541><B542>2-(2,6-dioxopipéridin-3-yl)-phtalimides et 1-oxoisoindolines substituées et procédé pour réduire les niveaux de TNF alpha</B542></B540><B560><B561><text>WO-A-98/03502</text></B561><B561><text>US-A- 5 463 063</text></B561><B561><text>US-A- 5 635 517</text></B561><B562><text>NIWAYAMA S ET AL: "POTENT INHIBITION OF TUMOR NECROSIS FACTOR-ALPHA PRODUCTION BY TETRAFLUOROTHALIDOMIDE AND TETRAFLUOROPHTHALAMIDES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON., US, vol. 39, no. 16, 1 January 1996 (1996-01-01), page 3044/3045, XP002048231 ISSN: 0022-2623</text></B562><B562><text>HE WEIXUAN ET AL: "Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease." ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 206, no. 1-2, 1993, page MEDI 216, XP009001980 206th ACS;Chicago, Illinois, USA; August 22-27, 1993 ISSN: 0065-7727</text></B562><B562><text>WNENDT ET AL: "Enantioselective inhibition of TNF-.alpha. release by thalidomide and thalidomide-analogs" CHIRALITY, WILEY-LISS, NEW YORK, US, vol. 8, 1996, pages 390-396, XP002074569 ISSN: 0899-0042</text></B562><B562><text>MIYACHI H ET AL: "Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: Influence of substituents at the phthaloyl moiety on the activity and stereoselectivity" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 46, no. 7, July 1998 (1998-07), pages 1165-1168, XP002107774 ISSN: 0009-2363</text></B562><B562><text>MULLER GEORGE W ET AL: "Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production." BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 11, 7 June 1999 (1999-06-07), pages 1625-1630, XP004169632 ISSN: 0960-894X</text></B562></B560></B500><B600><B620><parent><pdoc><dnum><anum>02012942.5</anum><pnum>1285916</pnum></dnum><date>20020611</date></pdoc><pdoc><dnum><anum>97936295.1</anum><pnum>0925294</pnum></dnum><date>19980129</date></pdoc></parent></B620><B620EP><parent><cdoc><dnum><anum>10183268.1</anum><pnum>2305663</pnum></dnum><date>20100930</date></cdoc></parent></B620EP></B600><B700><B720><B721><snm>Muller, George W</snm><adr><str>P.O.Box 3688</str><city>Rancho Santa Fe, CA 92067</city><ctry>US</ctry></adr></B721><B721><snm>Stirling, David</snm><adr><str>3281 Round Hill Road</str><city>Branchburg, NJ 08876</city><ctry>US</ctry></adr></B721><B721><snm>Chen, Roger, Shen-Chu</snm><adr><str>110 Christie Street</str><city>Edison, NJ 08820</city><ctry>US</ctry></adr></B721></B720><B730><B731><snm>CELGENE CORPORATION</snm><iid>100096655</iid><irf>AXH/47056EP3</irf><adr><str>7 Powder Horn Drive</str><city>Warren, NJ 07059</city><ctry>US</ctry></adr></B731></B730><B740><B741><snm>Hutter, Anton</snm><sfx>et al</sfx><iid>101053823</iid><adr><str>Venner Shipley LLP 
20 Little Britain</str><city>London
EC1A 7DH</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>CH</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>IE</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>MC</ctry><ctry>NL</ctry><ctry>PT</ctry><ctry>SE</ctry></B840><B880><date>20090617</date><bnum>200925</bnum></B880></B800></SDOBI>
</ep-patent-document>
